These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Double-blind crossover trial comparing systemic chromosome-carboxylic acid with placebo in patients with atopic dermatitis. Kavli G; Larsen PO Allergy; 1981 Nov; 36(8):597-600. PubMed ID: 7039401 [TBL] [Abstract][Full Text] [Related]
3. Clinical trial of a new chromone compound for systemic treatment of atopic dermatitis. Larsen PO; Larsen FS Acta Derm Venereol; 1979; 59(3):270-1. PubMed ID: 87092 [TBL] [Abstract][Full Text] [Related]
4. Lack of preventing effect of systemically and topically administered histamine H(1) or H(4) receptor antagonists in a dog model of acute atopic dermatitis. Bäumer W; Stahl J; Sander K; Petersen LJ; Paps J; Stark H; Kietzmann M; Olivry T Exp Dermatol; 2011 Jul; 20(7):577-81. PubMed ID: 21521369 [TBL] [Abstract][Full Text] [Related]
5. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Kimata H Ann Allergy Asthma Immunol; 1999 Mar; 82(3):293-5. PubMed ID: 10094221 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, vehicle-controlled, half-side comparison with a herbal ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica for the treatment of mild-to-moderate atopic dermatitis. Klövekorn W; Tepe A; Danesch U Int J Clin Pharmacol Ther; 2007 Nov; 45(11):583-91. PubMed ID: 18077922 [TBL] [Abstract][Full Text] [Related]
7. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E; Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675 [TBL] [Abstract][Full Text] [Related]
8. Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and SLS-inflamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study. Thomsen JS; Benfeldt E; Jensen SB; Serup J; Menné T Acta Derm Venereol; 2002; 82(1):30-5. PubMed ID: 12013195 [TBL] [Abstract][Full Text] [Related]
10. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Fadel R; Ramboer I; Chatterjee N; Rihoux JP; Derde MP Allergy; 2000 Apr; 55(4):382-5. PubMed ID: 10782524 [TBL] [Abstract][Full Text] [Related]
11. Effect of topical cromoglycate solution on atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral anti-allergic medication, oxatomide. Kimata H; Hiratsuka S Eur J Pediatr; 1994 Feb; 153(2):66-71. PubMed ID: 7908877 [TBL] [Abstract][Full Text] [Related]
12. Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Jenks PJ; Kavanagh GM; Brooks J; Bradfield JW; Archer CB Clin Exp Dermatol; 1999 Mar; 24(2):112-7. PubMed ID: 10233666 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial. Mehrbani M; Choopani R; Fekri A; Mehrabani M; Mosaddegh M; Mehrabani M J Ethnopharmacol; 2015 Aug; 172():325-32. PubMed ID: 26151244 [TBL] [Abstract][Full Text] [Related]
14. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin. Sansom JE; Brooks J; Burton JL; Archer CB Clin Exp Dermatol; 1996 Jan; 21(1):33-7. PubMed ID: 8689766 [TBL] [Abstract][Full Text] [Related]
15. Subpopulations of lymphocytes and lymphocyte transformation tests in atopic dermatitis: evaluation of a systemic treatment with a new chromone compound and comparison with a normal group. Birkeland SA; Larsen PO; Larsen FS J Invest Dermatol; 1981 May; 76(5):367-70. PubMed ID: 7014726 [TBL] [Abstract][Full Text] [Related]
16. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL; Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204 [TBL] [Abstract][Full Text] [Related]
17. Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic) on intradermal skin test reactivity in atopic dogs. Marsella R; Nicklin CF; Saglio S; Lopez J Vet Dermatol; 2004 Aug; 15(4):218-24. PubMed ID: 15305928 [TBL] [Abstract][Full Text] [Related]
18. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Cheer SM; Plosker GL Am J Clin Dermatol; 2001; 2(6):389-406. PubMed ID: 11770393 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous reactions to substance P and histamine in atopic dermatitis. Coulson IH; Holden CA Br J Dermatol; 1990 Mar; 122(3):343-9. PubMed ID: 1691013 [TBL] [Abstract][Full Text] [Related]
20. Anti-Pruritic Efficacy of Itch Relief Lotion and Cream in Patients With Atopic History: Comparison With Hydrocortisone Cream. Zirwas MJ; Barkovic S J Drugs Dermatol; 2017 Mar; 16(3):243-247. PubMed ID: 28301620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]